

Juan Pablo Arab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6492389/publications.pdf>

Version: 2024-02-01

121
papers

4,300
citations

136740

32
h-index

133063

59
g-index

144
all docs

144
docs citations

144
times ranked

5570
citing authors

#	ARTICLE	IF	CITATIONS
1	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. <i>Hepatology</i> , 2017, 65, 350-362.	3.6	444
2	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 321-350.	9.6	387
3	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
4	Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 584-599.	1.9	194
5	Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. <i>Hepatology International</i> , 2018, 12, 24-33.	1.9	149
6	Mechanical Stretch Increases Expression of CXCL1 in Liver Sinusoidal Endothelial Cells to Recruit Neutrophils, Generate Sinusoidal Microthrombi, and Promote Portal Hypertension. <i>Gastroenterology</i> , 2019, 157, 193-209.e9.	0.6	134
7	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. <i>Nature Communications</i> , 2019, 10, 3126.	5.8	124
8	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 65-72.	3.7	108
9	An Open-label, Dose-escalation Study to Assess the Safety and Efficacy of IL-22 Agonist Fc652 in Patients With Alcohol-associated Hepatitis. <i>Hepatology</i> , 2020, 72, 441-453.	3.6	107
10	Liver Dysfunction as a Novel Player in Alzheimer's Progression: Looking Outside the Brain. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 174.	1.7	93
11	Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. <i>Frontiers in Medicine</i> , 2020, 7, 448.	1.2	75
12	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2020, 19, 674-690.	0.6	72
13	Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). <i>Annals of Hepatology</i> , 2019, 18, 518-535.	0.6	69
14	Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis. <i>Scientific Reports</i> , 2017, 7, 3491.	1.6	68
15	Reducing the Global Burden of Alcohol-associated Liver Disease: A Blueprint for Action. <i>Hepatology</i> , 2021, 73, 2039-2050.	3.6	63
16	Aquaporin-1 Promotes Angiogenesis, Fibrosis, and Portal Hypertension Through Mechanisms Dependent on Osmotically Sensitive MicroRNAs. <i>American Journal of Pathology</i> , 2011, 179, 1851-1860.	1.9	61
17	CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study. <i>Vaccine</i> , 2016, 34, 1889-1895.	1.7	59
18	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021, 75, 1026-1033.	1.8	59

#	ARTICLE	IF	CITATIONS
19	High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. <i>World Journal of Gastroenterology</i> , 2020, 26, 7693-7706.	1.4	59
20	Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. <i>Current Gastroenterology Reports</i> , 2017, 19, 43.	1.1	58
21	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021, 73, 571-585.	3.6	56
22	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021, 41, 421-434.	1.8	55
23	Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF- β 2 Dependent Hepatic Stellate Cell Activation and Liver Fibrosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 197-209.	2.3	54
24	Impact of COVID-19 on liver transplant recipientsâ€”A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 38, 101025.	3.2	54
25	Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2407-2416.e8.	2.4	52
26	Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. <i>World Journal of Gastroenterology</i> , 2014, 20, 12182.	1.4	51
27	UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. <i>Handbook of Experimental Pharmacology</i> , 2019, 256, 237-264.	0.9	51
28	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 45-59.	8.2	50
29	Beneficial effects of mineralocorticoid receptor blockade in experimental nonâ€”alcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 2129-2138.	1.9	48
30	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. <i>Advances in Therapy</i> , 2021, 38, 2130-2158.	1.3	46
31	The Lâ€”lysophosphatidylinositol/G Proteinâ€”Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis. <i>Hepatology</i> , 2021, 73, 606-624.	3.6	42
32	Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. <i>Nature Communications</i> , 2021, 12, 4560.	5.8	37
33	Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy. <i>Cells</i> , 2020, 9, 817.	1.8	36
34	Gut microbiota in nonâ€”alcoholic fatty liver disease and alcoholâ€”related liver disease: Current concepts and perspectives. <i>Hepatology Research</i> , 2020, 50, 407-418.	1.8	35
35	Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. <i>Journal of Hepatology</i> , 2020, 73, 149-160.	1.8	35
36	Bile Acids in Cholestasis and its Treatment. <i>Annals of Hepatology</i> , 2017, 16, S53-S57.	0.6	34

#	ARTICLE	IF	CITATIONS
37	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 849-866.	1.4	32
38	Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. <i>Liver International</i> , 2020, 40, 2888-2905.	1.9	32
39	Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 451-461.	1.9	32
40	Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165753.	1.8	31
41	Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165857.	1.8	27
42	Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study. <i>Hepatology</i> , 2021, 74, 2478-2490.	3.6	27
43	High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. <i>Annals of Hepatology</i> , 2016, 15, 721-8.	0.6	26
44	Alcohol Consumption: Medical Implications, the Liver and Beyond. <i>Alcohol and Alcoholism</i> , 2022, 57, 283-291.	0.9	25
45	The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 552-559.	3.7	25
46	Management of <i>Helicobacter pylori</i> infection in Latin America: A Delphi technique-based consensus. <i>World Journal of Gastroenterology</i> , 2014, 20, 10969.	1.4	23
47	Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1339.	1.8	22
48	Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. <i>Journal of Physiology and Biochemistry</i> , 2014, 70, 667-674.	1.3	21
49	The evolving role of liver biopsy in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2018, 17, 899-902.	0.6	21
50	NAFLD: Challenges and opportunities to address the public health problem in Latin America. <i>Annals of Hepatology</i> , 2021, 24, 100359.	0.6	20
51	GIPC-Regulated IGFBP-3 Promotes HSC Migration In Vitro and Portal Hypertension In Vivo Through a β 1-Integrin Pathway. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 545-559.	2.3	19
52	Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101675.	0.7	19
53	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e289-e297.	2.4	17
54	Early Diagnosis and Prevention of Infections in Cirrhosis. <i>Seminars in Liver Disease</i> , 2022, 42, 293-312.	1.8	17

#	ARTICLE	IF	CITATIONS
55	Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1141-1157.	1.4	16
56	Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. <i>JCI Insight</i> , 2017, 2, .	2.3	16
57	Baveno VI and Expanded Baveno VI criteria successfully predicts the absence of high-risk gastroesophageal varices in a Chilean cohort. <i>Liver International</i> , 2020, 40, 1427-1434.	1.9	15
58	Current Medical Treatment for Alcohol-Associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1333-1348.	0.4	15
59	Effects of Japanese herbal medicine inchin-ko-to on endotoxin-induced cholestasis in the rat. <i>Annals of Hepatology</i> , 2009, 8, 228-233.	0.6	14
60	Reanimación cardiopulmonar básica: conocimiento teórico, desempeño práctico y efectividad de las maniobras en médicos generales. <i>Revista Medica De Chile</i> , 2012, 140, 73-77.	0.1	14
61	Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2011, 10, 493-501.	0.6	13
62	Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement. Current Treatment Options in Gastroenterology, 2022, 20, 261-278.	0.3	13
63	Statins and portal hypertension: A tale of two models. <i>Hepatology</i> , 2016, 63, 2044-2047.	3.6	12
64	COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	12
65	Public Health Measures and Prevention of Alcohol-Associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1480-1491.	0.4	12
66	Alcohol-Related Liver Disease in Latin America: Local Solutions for a Global Problem. <i>Clinical Liver Disease</i> , 2020, 16, 187-190.	1.0	11
67	Are We Really Taking Care of Alcohol-Related Liver Disease in Latin America?. <i>Clinical Liver Disease</i> , 2020, 16, 91-95.	1.0	11
68	Hospitalizations for Acute on Chronic Liver Failure at Academic Compared to Non-academic Centers Have Higher Mortality. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1306-1314.	1.1	11
69	Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV. <i>JAMA Network Open</i> , 2021, 4, e2120929.	2.8	11
70	Black hairy tongue during interferon therapy for hepatitis C. <i>Annals of Hepatology</i> , 2015, 14, 414-415.	0.6	10
71	Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. <i>World Journal of Hepatology</i> , 2016, 8, 1075.	0.8	10
72	Bile Acids and Portal Hypertension. <i>Annals of Hepatology</i> , 2017, 16, S83-S86.	0.6	8

#	ARTICLE	IF	CITATIONS
73	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. <i>Future Science OA</i> , 2020, 6, FSO441.	0.9	8
74	Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice. <i>Annals of Hepatology</i> , 2021, 24, 100357.	0.6	8
75	The Mortality Index for Alcohol-Associated Hepatitis: A Novel Prognostic Score. <i>Mayo Clinic Proceedings</i> , 2022, 97, 480-490.	1.4	8
76	Mild hypothermia does not affect liver regeneration after partial hepatectomy in mice. <i>Liver International</i> , 2009, 29, 344-348.	1.9	7
77	Hepatic encephalopathy in a liver transplant recipient with stable liver function. <i>Hepatology</i> , 2013, 57, 1672-1674.	3.6	7
78	Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030?. <i>Clinical Liver Disease</i> , 2021, 18, 72-75.	1.0	7
79	Effects of bile acid sequestration on hepatic steatosis in obese mice. <i>Annals of Hepatology</i> , 2014, 13, 105-112.	0.6	6
80	Intrahepatic portal vein blood volume estimated by non-contrast magnetic resonance imaging for the assessment of portal hypertension. <i>Magnetic Resonance Imaging</i> , 2015, 33, 970-977.	1.0	6
81	Fragmento sÁ©rico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcoh³lica en poblaci³n chilena. <i>GastroenterologÁa Y HepatologÁa</i> , 2017, 40, 388-394.	0.2	6
82	XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. <i>Frontiers in Physiology</i> , 2021, 12, 664222.	1.3	6
83	Factors Having an Impact on Relapse and Survival in Transplant Recipients With Alcohol-Induced Liver Disease. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 1153-1164.	1.2	6
84	Prophylactic Perioperative Terlipressin Therapy for Preventing Acute Kidney Injury in Living Donor Liver Transplant Recipients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 417-427.	0.4	5
85	Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 398-404.	0.7	5
86	Vaccination against <scp>COVID</scp>â€19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis. <i>Liver International</i> , 2022, 42, 942-944.	1.9	5
87	Effects of Japanese herbal medicine Inchin-ko-to on endotoxin-induced cholestasis in the rat. <i>Annals of Hepatology</i> , 2009, 8, 228-33.	0.6	5
88	Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate. <i>Alcohol and Alcoholism</i> , 2022, 57, 576-580.	0.9	5
89	Early warning of liver disease in diabetics. <i>Annals of Hepatology</i> , 2010, 9, 307-309.	0.6	4
90	Higher Frequency of Hospital-Acquired Infections but Similar In-Hospital Mortality Among Admissions With Alcoholic Hepatitis at Academic vs. Non-academic Centers. <i>Frontiers in Physiology</i> , 2020, 11, 594138.	1.3	4

#	ARTICLE	IF	CITATIONS
91	Diagnosis of Alcohol-Associated Hepatitis. <i>Clinics in Liver Disease</i> , 2021, 25, 571-584.	1.0	4
92	Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. <i>Annals of Hepatology</i> , 2015, 14, 752-755.	0.6	3
93	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017, 16, 286-292.	0.4	3
94	462 “ Circulating Extracellular Vesicles and Sphingolipids Cargo are Highly Accurate Novel Biomarkers for Diagnosis of Alcoholic Hepatitis. <i>Gastroenterology</i> , 2019, 156, S-98.	0.6	3
95	Living Donor Liver Transplantation for Imatinib-Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology. <i>Liver Transplantation</i> , 2020, 26, 945-948.	1.3	3
96	Quantitative assessment of portal hypertension with bi-parametric dual-frequency hepatic MR elastography in mouse models. <i>European Radiology</i> , 2021, 31, 2303-2311.	2.3	3
97	Socioeconomic inequalities in the incidence of alcohol-related liver disease in the Latin American context. <i>Lancet Regional Health - Europe</i> , The, 2021, 10, 100229.	3.0	3
98	LDL particle size and antioxidant HDL function improve after sustained virological response in patients with chronic HCV. <i>Annals of Hepatology</i> , 2022, 27, 100555.	0.6	3
99	<i>Liver Disease</i> . , 2012, , 289-296.		2
100	Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population. <i>Gastroenterology & Hepatology (English Edition)</i> , 2017, 40, 388-394.	0.0	2
101	Sa1460 - Extracellular Vesicle C16 Ceramide and S1P Content in Alcoholic Hepatitis Correlates with Disease Severity and Resolution. <i>Gastroenterology</i> , 2018, 154, S-1120.	0.6	2
102	Triple-Phase Computed Tomography May Replace Dual-Energy X-ray Absorptiometry Scan for Evaluation of Osteoporosis in Liver Transplant Candidates. <i>Liver Transplantation</i> , 2021, 27, 341-348.	1.3	2
103	Insulin resistance and liver histopathology in metabolically unhealthy subjects do not correlate with the hepatic abundance of NLRP3 inflammasome nor circulating IL-1 ^β levels. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001975.	1.2	2
104	Early warning of liver disease in diabetics. <i>Annals of Hepatology</i> , 2010, 9, 307-9.	0.6	2
105	Black hairy tongue during interferon therapy for hepatitis C. <i>Annals of Hepatology</i> , 2015, 14, 414-5.	0.6	2
106	Achieving protection against HBV in HIV patients: Finding the best strategy. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3166-3167.	1.4	1
107	892 - Transcriptional Dysregulation of Inflammatory Gene Networks in Alcoholic Hepatitis is Associated with Genomewide Reconfiguration of Epigenetic States. <i>Gastroenterology</i> , 2018, 154, S-1109.	0.6	1
108	Old Remedies to Heal the Liver: Novel Effects of Digoxin in Hepatic Sterile Inflammation. <i>Hepatology</i> , 2019, 69, 904-906.	3.6	1

#	ARTICLE	IF	CITATIONS
109	804 - Integrin Based Angiocrine Signals Recruit Neutrophils to Drive Portal Hypertension in Congestive Hepatopathy. Gastroenterology, 2018, 154, S-1107.	0.6	0
110	Pulsatile Epigastric Mass and Liver Masses in a 38-Year-Old Patient With Splenomegaly Since Childhood. Gastroenterology, 2021, 161, e14-e16.	0.6	0
111	Editorial: trends in alcohol use and alcohol-associated liver disease in the US population—authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 513-514.	1.9	0
112	P-30 IMPACT OF PUBLIC HEALTH POLICIES ON ALCOHOL-ASSOCIATED LIVER DISEASE IN LATIN AMERICA: AN ECOLOGICAL MULTI-NATIONAL STUDY. Annals of Hepatology, 2021, 24, 100394.	0.6	0
113	P-41 TRENDS IN HOSPITALIZATION, CHARACTERISTICS AND MORTALITY OF HOSPITALIZED PATIENTS WITH CIRRHOSIS IN CHILE. Annals of Hepatology, 2021, 24, 100405.	0.6	0
114	Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH. , 2020, , 225-236.		0
115	Sending an SOS: Healing the Liver with the Bone Marrow. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	0
116	Hepatology Highlights. Hepatology, 2022, 75, 241-242.	3.6	0
117	Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. Annals of Hepatology, 2015, 14, 752-5.	0.6	0
118	Hepatology Highlights. Hepatology, 2022, 75, 775-776.	3.6	0
119	Hepatology highlights. Hepatology, 2022, 75, 1071-1072.	3.6	0
120	Letter: elevated liver enzymes and outcomes in COVID Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1235-1236.	1.9	0
121	Hepatology highlights. Hepatology, 2022, 75, 1363-1364.	3.6	0